The present study was aimed at devising an efficient nonviral strategy for suicide gene therapy of hepatocellular carcinoma (HCC). To improve the efficiency of DNA delivery and expression, we applied Epstein-Barr virus (EBV)-based plasmid vectors instead of conventional plasmid vectors and combined them with cationic liposome (EBV/lipoplex) or polyamidoamine dendrimer (PAAD) (EBV/polyplex). When the ␤-galactosidase gene was transferred to HuH7, PLC/PRF/5, or HLE cells, Յ50-fold higher ␤-galactosidase activities were demonstrated in the cells transfected with EBV vector compared with those transfected with conventional plasmid vectors. PAAD-mediated transfection of HCC with pSES.Tk (an EBV-based vector carrying the herpes simplex virus-1 thymidine kinase gene) resulted in a marked reduction in viable cell number by the addition of ganciclovir (GCV). The HCC cells transfected with pSES.Tk/PAAD showed 100-to 1000-fold higher susceptibilities to GCV than those transfected with pS.Tk (a conventional plasmid vector carrying herpes simplex virus-1 thymidine kinase gene)/PAAD. The pSES.Tk-transfected HCC cells were effectively killed by day 9 in culture with a clinically feasible concentration of GCV (25 M), whereas the pS.Tk-transfected cells survived the culture. These results demonstrate highly efficient suicide gene transfer into various HCC cells by EBV-based plasmid vectors in vitro, suggesting the possible application of this nonviral vector system to gene therapy of HCC. Cancer Gene Therapy (2000) 7, 27-36
H epatocellular carcinoma (HCC) is one of the most common and ominous malignancies in humans. Despite recent advances in HCC therapy, including liver transplantation, the cure rate for HCC remains low. 1 Gene therapy modalities may provide an additional strategy for treatment. We focused on nonviral vector systems as a means of suicide gene therapy of HCC.
Generally, a nonviral vector system consists of two components: a plasmid vector (expression vector) and a gene delivery vehicle (nonviral vector). Improvements of both components are considered to be important to make a nonviral vector system sufficiently useful for human gene therapy. With regard to the gene delivery vehicles, a number of methods have been devised, including those using liposomes, synthetic polymers, and physical means such as electroporation and a gene gun. [2] [3] [4] [5] [6] Despite the recent progress in these techniques, the transfection/expression efficiency of nonviral systems remains relatively poor as long as conventional plasmid vectors are used. Less effort has been made to improve plasmid vectors, although some novel promoter/enhancers are being actively investigated. [7] [8] [9] [10] We substituted Epstein-Barr virus (EBV)-based plasmid vectors for the conventional plasmid vectors and employed them as a component of practical nonviral vector systems in HCC.
EBV-based episomal vectors are plasmid vectors carrying the EBV nuclear antigen 1 (EBNA1) gene and the oriP region from EBV as trans and cis elements for DNA replication, respectively. 11, 12 Through binding to oriP, EBNA1 facilitates the retention, nuclear localization, and replication of the plasmid DNA, [13] [14] [15] [16] [17] giving the EBV vector favorable features of an artificial chromosome. We have demonstrated that extremely efficient transfection can be achieved with EBV-based episomal vectors by means of electroporation in lymphoma cell lineage. 18, 19 In the present study, we transferred the herpes simplex virus-1 (HSV-1) thymidine kinase (Tk) gene 20 -22 in vitro into three HCC cell lines via an EBV-based episomal vector coupled with polyamidoamine dendrimer (PAAD). The high sensitivity of the transfected cells to ganciclovir (GCV) may suggest the possible application of this vector system to the gene therapy of HCC.
MATERIALS AND METHODS

Plasmid vectors
Plasmid vectors were constructed as described previously. 21, 22 pSES.␤ (Fig 1, upper left panel) and pSES.Tk (Fig 1, upper right  panel) are composed of (a) the Escherichia coli ␤-galactosidase (␤-gal) gene (derived from pSV␤ (Clontech, Palo Alto, Calif)) (pSES.␤) or the HSV-1 Tk gene (derived from pHSV-106 (Life Technologies, Gaithersburg, Md)) (pSES.Tk), located between the SR␣ promoter (HindIII-XhoI 0.6-kilobase fragment from pcDL-SR␣296 23 ) and the simian virus 40 (SV40) poly(A) additional signal, (b) EBV oriP (derived from p220.2 12 ), (c) the EBV EBNA1 gene (derived from p220.2) under the control of the SR␣ promoter (ClaI-ClaI 0.9-kilobase fragment from pcDL-SR␣296), and (d) the ampicillin-resistant gene and the Col E1 replication origin. pS.␤ (Fig 1, lower left panel) and pS.Tk (Fig 1, lower right panel) were constructed from pSES.␤ and pSES.Tk, respectively, by deleting SR␣-EBNA1 and oriP.
Cells
The human HCC cell lines HLE, PLC/PRF/5, and HuH-7 (Health Science Research Resources Bank, Osaka, Japan), were passaged in Dulbecco's modified Eagle's medium (Life Technologies) supplemented with 10% fetal bovine sera (Life Technologies), 100 U/mL of ampicillin, and 100 g/mL of streptomycin (complete medium).
Transfection by cationic liposomes
For cationic liposome-mediated transfection, cells were seeded into the wells of a six-well plate (Becton Dickinson Labware, Franklin Lakes, NJ) and allowed to proliferate until they were 70 -80% confluent. Shortly before transfection, the culture medium was replaced with 1 mL of fresh complete medium. Plasmid DNA (1.5 g) was mixed with various amounts of 1,3-di-oleoyloxy-2-(6-carboxy-spermyl)-propylamide (DOSPER) (Boehringer Mannheim, Mannheim, Germany) to a final volume of 100 L. After incubation at room temperature for 15 minutes, 100 L of the plasmid DNA-cationic liposome complex was added to the culture, which was then incubated at 37°C in 5% CO 2 /95% humidified air. After 6 hours, the culture medium was replaced with fresh medium, and the cells were further cultured until they were subjected to the ␤-gal assay.
Transfection by PAAD
Cells were seeded into the wells of a six-well plate (Becton Dickinson Labware) at a density of 3 ϫ 10 5 cells/well and incubated at 37°C in 5% CO 2 /95% humidified air. On the following day, 2 g of DNA was mixed with various amounts of PAAD (generation 5) (Superfect) (Qiagen, Hilden, Germany) in Dulbecco's modified Eagle's medium and incubated for 10 minutes at room temperature. The complex was added with 600 L of complete medium and immediately transferred to the cells that had been washed with phosphate-buffered saline (PBS). The cells were incubated at 37°C in 5% CO 2 /95% humidified air for 2 hours, followed by replacement with fresh complete medium. After further incubation for appropriate periods, the cells were subjected to ␤-gal assay, 5-bromo-4-chloro-3-indolyl ␤-D-galactoside (X-Gal) staining, or Alamar blue assay.
␤-gal assay
Cells were scraped off dishes, washed twice with PBS, and resuspended in 50 L of tris(hydroxymethyl)aminomethaneHCl (pH 7.8). After two cycles of freezing and thawing, the lysate was centrifuged at 15,000 revolutions per minute for 5 minutes. The ␤-gal activity in the cell supernatant fraction was assayed with a ␤-gal assay kit (Invitrogen, San Diego, Calif) according to the manufacturer's protocol. The optical density (OD) was measured at 420 nm. Activities were calculated using the following formula: ␤-gal units ϭ ([OD 420 ϫ 380]/30)/ mg protein, where 380 is a conversion factor and 30 is the time of incubation in minutes. The protein concentration of the supernatant was assessed according to the method of Bradford. 24 
X-Gal staining
Cells were fixed with 1% glutaraldehyde/PBS for 10 minutes, washed three times with PBS, and subsequently incubated in X-Gal staining solution (0.05% (v/v) X-Gal (Nacalai Tesque, Kyoto, Japan), 1 mM MgCl 2 , 150 mM NaCl, 3 mM K 4 (Fe(CN) 6 ), 3 mM K 3 (Fe(CN) 6 ), 60 mM Na 2 HPO 4 , 40 mM NaH 2 PO 4 , and 0.1% Triton X-100) for 3 hours at 37°C. The reaction was terminated by replacing the solution with 1 mM Na 2 -ethylenediaminetetraacetic acid/PBS. 
Alamar blue assay
The susceptibility of cells to GCV was examined by Alamar blue assay. 25, 26 Briefly, quadruplicate aliquots of cells were seeded in 96-well, flat-bottom microtiter plates (Falcon, Lincoln Park, NJ) (5 ϫ 10 3 cells in 200 L of complete medium per well). After 24 hours, GCV (Tanabe, Tokyo, Japan) was added at various concentrations ranging from 0 to 10,000 M. After further incubation in 5% CO 2 /95% humidified air at 37°C for 96 hours, Alamar blue (Alamar Biosciences, Sacramento, Calif) was added according to the manufacturer's protocol. The cells were further cultured for 4 hours, and the OD of each well was measured with a microplate reader at test and reference wavelengths of 570 and 600 nm, respectively. The percentages of viable cells were calculated according to the following formula: % viable cells ϭ (OD 570 Ϫ OD 600 ) of GCV-treated cells/(OD 570 Ϫ OD 600 ) of untreated cells.
RESULTS
EBV-based episomal vector/cationic liposome complex (EBV/lipoplex) as an efficient nonviral system to transfect HCC cells in vitro To examine whether EBV-based episomal vectors can be combined successfully with nonviral gene delivery systems, we transfected HCC cell lines with pSES.␤ or pS.␤ (see Fig 1) encapsulated with cationic liposome and PAAD. The ␤-gal activities were measured after appropriate periods of culture. First, the optimal preparation and transfection conditions were determined for cationic liposome-mediated transfection into HLE cells. Various ratios of cationic liposome to DNA were tested. At every ratio, transfection of the EBV-based episomal vector (pSES.␤) resulted in higher ␤-gal activity compared with that of the conventional plasmid vector (pS.␤) at 60 hours posttransfection (Fig 2A) . Maximal ␤-gal activity was obtained by mixing 1.5 g of DNA with 6 g of cationic liposome; at this optimal condition, ϳ12-fold higher enzyme activity was obtained with pSES.␤ compared with pS.␤.
Next, we estimated the efficiency of transfection/ expression in three HCC cell lines using the EBV/ cationic liposome. Experimental conditions were optimized for each cell line (data not shown). On day 4 posttransfection, the transfection efficiency by pSES.␤/ cationic liposome was ϳ20-, ϳ2.8-, and ϳ11-fold higher than that provided by pS.␤/cationic liposome in HLE, PLC/PRF/5, and HuH-7 cells, respectively (Fig 2B) . Even on day 8 posttransfection, the levels of ␤-gal were still much higher in the cells transfected with pSES.␤ than in the pS.␤-transfected cells. The results indicated that transfection by EBV-based episomal vectors combined with cationic liposome was much more efficient than that by non-EBV conventional vector/cationic liposome.
Highly efficient transfection into HCC cells by EBVbased episomal vector/PAAD complex (EBV/polyplex)
Next, we tried to combine an EBV vector with PAAD, which has been reported to be more effective than cationic liposome in some experimental systems. 27 In our first series of experiments, several different ratios of DNA to PAAD were tested for HLE cells (Fig 3A) . The highest ␤-gal activity was observed when 15 g of PAAD and 2 g of pSES.␤ were used. At this optimal preparation, the pSES.␤/PAAD yielded 30-fold higher ␤-gal activity compared with the optimal preparation of pS.␤/ PAAD.
We also estimated the efficiency of transfection/expression in the other HCC cell lines by the EBV vector/PAAD. The experimental condition was also optimized for each cell line (data not shown). ␤-gal activity was ϳ50-fold (HLE), ϳ28-fold (PLC/PRF/5), and ϳ10-fold (HuH-7) stronger in pSES.␤-transfected cells than pS.␤-transfected cells on day 4 posttransfection (Fig 3B) . ␤-gal expression was also demonstrated by the X-Gal staining of HLE cells transfected with pSES.␤ or pS.␤/ PAAD under optimal conditions. As shown in Figure 4 , ϳ35% of the cells transfected with pSES.␤/PAAD expressed ␤-gal on day 4 posttransfection, whereas only 3% of the pS.␤/PAAD-transfected cells were positive for this marker gene product.
Extremely high susceptibility to GCV of HCC cells transfected with pSES.Tk/PAAD We hypothesized that the highly efficient EBV-based episomal vector system may be useful in transferring a suicide gene into HCC. To assess this possibility, we constructed two plasmids (i.e., pSES.Tk, carrying the HSV-1 Tk gene expression unit, the EBNA1 gene, and oriP, and pS.Tk, carrying HSV-1 Tk but not EBNA1 or oriP) (Fig 1) . These plasmids were transfected into the HLE, PLC/PRF/5, and HuH-7 cell lines by means of PAAD. At 72 hours posttransfection, cells were cultured in the presence of various concentrations of GCV for 4 days; next, their viabilities were measured by Alamar blue assay. As shown in Figure 5 , the transfer of pS.Tk did not significantly affect the susceptibilities of the HLE and PLC/PRF/5 cells to GCV, whereas the the susceptibility of HuH-7 to GCV was moderately elevated. In contrast, the transfection of pSES.Tk/PAAD rendered all of the cell lines highly susceptible to GCV. The GCV-susceptibilities of HLE, PLC/PRF/5, and HuH-7 cells transfected with EBV-based vector/PAAD were ϳ250-, ϳ100-, and ϳ1000-fold higher than that of the cells transfected with non-EBV vector/PAAD, respectively.
HCC cells transfected by pSES.Tk/PAAD were effectively killed by a clinical dose of GCV To examine whether the elevated sensitivity to GCV given by pSES.Tk/PAAD had therapeutic significance, HCC cells that had been transfected as described above were cultured in the presence of 25 M of GCV; the numbers of cells were counted after 3, 6, and 9 days. We used 25 M of GCV because this dose was considered to be the standard sera GCV concentration in HCC patients administered ordinary clinical doses of GCV. 28 As shown in Figure 6 , HCC cells transfected with pSES.Tk/ PAAD were markedly reduced in cell number within 9 days of culture. In contrast, in the transfection by pS.Tk/PAAD, the reduction in viable cell number was less sufficient.
Transfection of pSES.Tk did not influence proliferation of HCC cells per se
We examined whether cell proliferation was affected by gene delivery with EBV-based vector. HLE, PLC/PRF/5, and HuH-7 cells were transfected with pSES.Tk or pS.Tk/PAAD. After 1 day, cells were resuspended in the conditioned medium and plated at a density of 3 ϫ 10 5 cells per 35-mm well. The numbers of cells were counted. As shown in Figure 7 , all of the cell lines exhibited growth curves that were comparable with those of the mock-transfected cells, regardless of the plasmids transfected. These results indicated that the introduction of the HSV-Tk gene, the EBNA1 gene, and oriP did not affect cell proliferation in the absence of GCV.
DISCUSSION
In the present study, we demonstrated that a suicide gene could be quite effectively transferred into human HCC cells in vitro by means of EBV-based episomal vectors coupled with synthetic macromolecules. Some groups, including us, have reported that plasmid vectors carrying oriP but not EBNA1 were quite effective in transferring the HSV-1 Tk gene in vitro into EBVassociated lymphoma cells; 29 -31 these particular cancer cells strongly express endogenous EBNA1, allowing very strong expression from oriP-bearing plasmids. However, to our knowledge, the present study is the first report showing that EBV-episomal vectors carrying both oriP and EBNA1 are quite effective in suicide gene transfer into HCC, which is an EBNA1-negative cancer.
In general, the advantage of EBV-based episomal vectors has been appreciated in long-term maintenance of the plasmid rather than in transient gene expression. However, we demonstrated that even at a transient phase, EBV-based episomal vectors combined with both delivery vehicles resulted in a markedly high expression of marker gene in all of the cell lines tested. The high transient expression by EBV-based episomal vectors may result from the multiple functions of EBNA1, such as nuclear transfer of the plasmid DNA, anchorage of the plasmid DNA to the nuclear matrix, and transcriptional enhancement. [13] [14] [15] [16] [17] The episomal replication may also contribute to the high transient transfection/expression by the EBV plasmids. However, the contribution may be small because (a) highly efficient transfection/expression can also be seen in rodent cells, in which the EBV-based plasmids cannot replicate, 32 and (b) even in human cells, the oriP-bearing plasmids replicate only once in each S phase, so unlike the SV40-based plasmid vectors, 33 the copy number of the EBV plasmids does not increase after transfection.
As far as we know, the present study is the first report in which PAAD was used to deliver EBV plasmid DNA into cells. In the comparison of the cationic liposome (DOSPER) and PAAD, the marker gene was more efficiently transferred by the latter than by the former. These results are consistent with an earlier study by Kukowska-Latallo et al showing the efficacy of PAAD in gene delivery. 27 However, many different cationic liposomes with different compositions have been devised, and some cationic liposomes other than DOSPER may work better with the EBV vectors.
The X-Gal staining experiments showed that ϳ35% of the pSES.␤-transfected HLE cells expressed the marker gene product on day 4 posttransfection (Fig 4) . Similarly, the positivity in the pSES.␤-transfected HuH-7 cells was ϳ45% (data not shown). In contrast, when pSES.Tk-transfected HuH-7 cells were cultured in the presence of 25 M of GCV, virtually 100% of the cells were killed during 9 days of culture (Fig 6) . This discrepancy may be explained by the so-called bystander effect. 34, 35 Indeed, Kuriyama et al have shown that 10 -20% of HSV-1 Tk-expressing cells was enough to kill nearly 100% of HCC cells when HSV-1 Tk-positive and -negative cells were mixed at various ratios. 33 Alternatively, a small proportion of mock-transfected cells was killed by GCV treatment (Fig 5) . A fraction of bystander cells might have been killed in a similar manner.
The present X-Gal staining experiments also showed that in the case of HLE cells, the ␤-gal positivity was ϳ12-fold higher in pSES.␤-transfected cells than in pS.␤-transfected cells (35% vs. 3%) (Fig 4) . In contrast, the ␤-gal enzyme activity in the pSES.␤-transfected HLE cells was ϳ50-fold higher than that in the pS.␤-transfected cells (Fig 3A) . Thus, the high level of expression by the EBV vectors may be attributed to both the high frequency of ␤-gal-positive cells and the high intensity of marker gene expression in each positive cell.
Specific targeting of cancer cells is important for the clinical application of cancer gene therapy strategies. In the case of HCC, the promoter/enhancer of the ␣-fetoprotein gene has been used successfully in combination with retroviral or adenoviral vectors. 8,36 -38 The ␣-fetoprotein promoter can be included in the EBV-based vectors to drive EBNA1 and/or HSV-1 Tk genes.
It has been shown that the PAAD can be applicable to in vivo gene delivery without apparent immunogenic or toxic effects. 39 Further studies in vivo are now underway for the evaluation of the efficacy and safety of our system.
